COMPANY PROFILE

coIMMUNE

Explore full profile

CoImmune | Innovation in Immunotherapy

Durham, United StatesFounded 2019Biotech & Life Sciences

Valuation $250–500M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About coIMMUNE

CoImmune is a privately held, clinical-stage immuno-oncology company focused on redefining cancer treatment through advanced cellular immunotherapies. The company operates in the biotechnology sector, specifically targeting both liquid and solid tumors. CoImmune's core technology platforms include allogeneic CAR CIK cells for liquid tumors and RNA-loaded dendritic cells for solid tumors. These platforms have shown clinical efficacy and safety in trials, offering promising alternatives to traditional CAR T therapies with reduced toxicity. The company's business model involves developing these therapies through clinical trials and eventually bringing them to market for pediatric and adult patients with acute lymphoblastic leukemia and advanced metastatic renal cell carcinoma. Revenue is generated through the development and commercialization of these proprietary therapies, targeting healthcare providers and institutions specializing in oncology.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Durham, United States
Employees: 9
Open positions: None listed
Dealroom signal: 26.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Nov 2020	$45M	$180M	Lucio Rovati	—
SERIES A✓Equity / VC	Jan 2020	$3.8M	$15M	DSC Investment	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

coIMMUNE website traffic

Latest recorded traffic for coIMMUNE is 600 monthly website visits, up 17.6% over the last three months. coIMMUNE's team grew 0% over the past year.

Latest monthly visits600 3-month web change+17.6% 1-year team growth0%

Monthly website visitsOct 2020–Nov 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VIVicinitasAdvancing a one-of-a-kind protein stabilization platform to develop novel therapeutics for cancer and genetic disorders	South San Francisco, United States	Operational	3	$65M	$260M
INInnoRNAProprietary LNP platform for effective mRNA delivery, enabling advanced nucleic acid therapeutics	Shenzhen, China	Operational
7676bioDegradation by design 76Bio aims to develop transformational therapies for patients with life-threatening disease by pioneering the next generation of	New York City, United States	Operational
WBWonjin BiotechnologyCreating new medicines to treat complex and chronic diseases	Suwon, South Korea	Operational
OTOrigami TherapeuticsDeveloping next-generation disease-modifying protein degraders and correctors	San Diego, United States	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
THThryvDiscovering and developing therapies for the treatment of Long QT syndrome	Laval, Canada	Operational
ONOncohostDevelops personalized strategies to maximize the success of cancer therapy	Hadera, Israel	Operational